Published in AIDS Weekly, June 24th, 2002
A novel nonnucleoside reverse transcriptase inhibitor (nNRTI), MV026048 is currently in preclinical development and is expected to enter phase I clinical studies in 2003.
Current nNRTIs share common resistance profiles, which may reduce the likelihood that a patient will benefit from a second currently approved nNRTI after failing therapy with a first nNRTI. Preclinical data for MV026048 indicate that this new generation compound has a unique resistance profile. A unique resistance profile could make MV026048 a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.